Literature DB >> 21105577

Involvement of cysteinyl leukotriene receptors in angiogenesis in rat thoracic aortic rings.

L Xu1, L Zhang, L Liu, S Fang, Y Lu, E Wei, W Zhang.   

Abstract

Cysteinyl leukotrienes (CysLTs) are potent inflammatory mediators that induce inflammation through the activation of CysLT1 and CysLT2 receptors. It has been reported that inflammatory mediators, such as prostaglandins, play an important role in angiogenesis. However, whether CysLTs and the receptor subtypes are involved in angiogenesis is not clarified. Here, we determined the effects of CysLT receptor agonist leukotriene D4 (LTD4) and antagonists on angiogenesis by rat thoracic aortic ring assay. We found that the microvessel growth in 25% serum-containing cultures was significantly inhibited by the CysLT1 receptor antagonist montelukast (0.1-1 microM), but not by the CysLT2 receptor antagonist BAY cyslt2 (0.1-1 microM). The microvessel growth in serum-free culture was affected neither by montelukast (0.01-1 microM) nor by BAY cyslt2 (0.1-1 microM). Furthermore, LTD4 at 100 nM significantly enhanced the microvessel growth in serum-free culture and LTD4 at 10-100 nM significantly enhanced the microvessel growth in 25% serum-containing cultures. The enhancement was abrogated by both montelukast and BAY cyslt2. Thus, CysLT1 receptors may mediate endogenously regulated microvessel growth in normal culture; whereas the exogenous agonist LTD4 induces angiogenesis through the activation of both CysLT1 and CysLT2 receptors. The CysLT receptor antagonists can be developed as angiogenesis inhibitors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21105577

Source DB:  PubMed          Journal:  Pharmazie        ISSN: 0031-7144            Impact factor:   1.267


  6 in total

1.  Cysteinyl leukotriene 2 receptor promotes endothelial permeability, tumor angiogenesis, and metastasis.

Authors:  Ernest Duah; Lakshminarayan Reddy Teegala; Vinay Kondeti; Ravi K Adapala; Venkateshwar G Keshamouni; Yoshihide Kanaoka; K Frank Austen; Charles K Thodeti; Sailaja Paruchuri
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-17       Impact factor: 11.205

2.  A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab.

Authors:  Clare T Butler; Alison L Reynolds; Miriam Tosetto; Eugene T Dillon; Patrick J Guiry; Gerard Cagney; Jacintha O'Sullivan; Breandán N Kennedy
Journal:  J Biol Chem       Date:  2016-12-29       Impact factor: 5.157

3.  Understanding the Interaction Between Prostaglandins and Toll-Like Receptors in Nicotine-Induced Rectal Tumor in Animals.

Authors:  Wang Peng; Li Changlu; Seshadri Sriram; Jiangang Liu
Journal:  Turk J Gastroenterol       Date:  2022-06       Impact factor: 1.555

Review 4.  Evaluation of Cysteinyl Leukotriene Signaling as a Therapeutic Target for Colorectal Cancer.

Authors:  Lorraine Burke; Clare T Butler; Adrian Murphy; Bruce Moran; William M Gallagher; Jacintha O'Sullivan; Breandán N Kennedy
Journal:  Front Cell Dev Biol       Date:  2016-09-21

5.  Phenotype-based Discovery of 2-[(E)-2-(Quinolin-2-yl)vinyl]phenol as a Novel Regulator of Ocular Angiogenesis.

Authors:  Alison L Reynolds; Yolanda Alvarez; Temitope Sasore; Nora Waghorne; Clare T Butler; Claire Kilty; Andrew J Smith; Carmel McVicar; Vickie H Y Wong; Orla Galvin; Stephanie Merrigan; Janina Osman; Gleb Grebnev; Anita Sjölander; Alan W Stitt; Breandán N Kennedy
Journal:  J Biol Chem       Date:  2016-02-04       Impact factor: 5.157

6.  Montelukast for Medical Delay in Flap Surgery.

Authors:  Maryam Iranpour; Ali Khodarahmi; Nima Khodarahmi; Mohammad Shafiee; Reza Malekpourafshar; Nozar Nakhaee
Journal:  World J Plast Surg       Date:  2020-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.